This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

New Firms Oppose Bid for Chiron

Three shareholders owning 12.3% of Chiron's (CHIR) stock say they oppose an offer by Novartis (NVS) to buy the shares that the Swiss company doesn't already own.

The announcement heightens the uncertainty of Novartis' takeover bid, which is worth $45 a share, or $5.1 billion. Novartis now owns 44% of Chiron.

News of the holdouts sent Chiron's stock to a 52-week high of $45.32, up 61 cents, or 1.4% for the day, on nearly twice the average daily volume. After hours, the stock slipped 3 cents.

The new opponents join ValueAct Capital, a San Francisco investment management firm, in vowing to vote against the deal. ValueAct owns 5.2% of Chiron's shares.

One of the dissidents, CAM North America LLC, announced the newest opposition in a filing with the Securities and Exchange Commission. New York-based CAM and two other investment advisory firms now resisting the bid -- Smith Barney Fund Management LLC and Salomon Brothers Asset Management Inc. -- hold about 23.2 million shares.

In order to complete the deal, Novartis needs approval by a majority of Chiron shareholders, excluding the stock controlled by Novartis. ValueAct owns about 9.8 million of Emeryville, Calif.-based Chiron's shares. Together, the four opponent firms own 17.5% of all Chiron shares. More importantly, their holdings represent about 30% of the shares eligible to vote.

"We believe the merger consideration offered by Novartis of $45 in cash per Chiron share is financially inadequate," says Richard A. Freeman, managing director of CAM North America, in a Jan. 25 letter to Chiron that was enclosed in the SEC filing.

Although Novartis raised its buyout bid to $45 a share in October after Chiron's board rejected an earlier $40-a-share proposal, Novartis says it won't pay more. Novartis already has announced how the various Chiron units -- vaccines, blood testing and biopharmaceuticals -- will be absorbed.

The deal has been approved by the Federal Trade Commission. It still requires clearance from the European Union and Chiron's shareholders.

A shareholders' rebellion creates a dilemma for both companies. Chiron has already signaled it would be better off being owned by someone else rather than being independent. If the shareholders say "no" and Novartis won't budge on price, the question would be: Could Chiron attract another buyer, knowing that Novartis owns a giant piece of the company?

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs